)Check for updatesReceived:11 October 2022 Revised:6 April 2023 Accepted:8 April 2023D0t:10.1111/ejh13983ORIGINALARTICLEHaematologyWILEYCardiovascular risk in chronic myeloid leukaemia:Amultidisciplinary consensus on screening and managementDragana Milojkovic1 Alexander R.Lyon2 Priyanka Mehta3Evangelia Dimitriadou4 Satarupa Choudhuri5 Charlotte ManistysNick Cheshire2 Kirsty Crozier7 Nanda Basker Karim AmerSimon Purcell Susan Tan10 Richard E.Clark11Hammersmith Hospital,London,UK2The Royal Brompton Hospital,London,UKAbstract3University Hospital Bristol,Bristol,UKIntroduction:Tyrosine kinase inhibitors (TKIs)have become the mainstay of treat-Maidstone Tunbridge Wells,Tunbridgement for chronic myeloid leukaemia(CML),but cardiovascular(CV)risk and exacerba-Wells.UKtion of underlying risk factors associated with TKIs have become widely debated.SNorthern Care Alliance,Manchester.UK6Barts Health NHS Trust and UniversityReal-world evidence reveals little application of CV risk factor screening or continuedCollege London,London.UKmonitoring within UK CML management.This consensus paper presents practical7Churchill Hospital,Oxford,UKrecommendations to assist healthcare professionals in conducting CV screening/aSouthampton General Hospital,comorbidity management for patients receiving TKIs.Southampton,UK9pfizer Ltd.London,UKMethods:We conducted a multidisciplinary panel meeting and two iterative sur-40Envision Pharma Group,Sydney.Australiaveys involving 10 CML specialists:five haematologists,two cardio-oncologists,one1Department of Molecular and Cinicalvascular surgeon,one haemato-oncology pharmacist and one specialist nurseCancer Medicine,University of Liverpool,Liverpool,UKpractitioner.Results:The panel recommended that patients commencing second-/third-CorrespondenceDragana Milojkovic,Hammersmith Hospital,generation TKIs undergo formal CV risk assessment at baseline,with additionalDu Cane Road,London W120HS,UKinvestigations and involvement of cardiologists/vascular surgeons for those withEmail:d.milojkovic@imperial.ac.ukhigh CV risk.During treatment,patients should undergo CV monitoring,with thenature and frequency of testing dependent on TKI and baseline CV risk.Forpatients who develop CV adverse events,decision-making around TKI interrup-tion,cessation or change should be multidisciplinary and balance CV andhaematological risk.Conclusion:The panel anticipates these recommendations will support healthcareprofessionals in implementing CV risk screening and monitoring.broadly and consis-tently,and thereby help optimise TKI treatment for CML.KEYWORDScardiovascular,chronic myeloid leukaemia,consensus,tyrosine kinase inhibitorThis is an open access artide under the terms of the Creative Commons Attribution-NonCommercial License,which permits use,distribution and reproduction in anymedium,provided the original work is properly cited and is not used for commercial purposes2023 The Authors.European Joumal of Haematology published by John Wiley Sons Ltd.Eur J Hae
